The proposed universal PFAS restriction is among the most consequential files in EU chemicals policy. It is approaching the point of political decision with real uncertainty still lingering. How that uncertainty is resolved will determine whether the measure ends up both environmentally protective and workable in practice.
Where the file actually stands
In January 2023, the national authorities of Denmark, Germany, the Netherlands, Norway and Sweden submitted a restriction dossier to the European Chemicals Agency (ECHA) proposing to restrict the manufacture, placing on the market and use of PFAS in the EEA. A six-month consultation followed in 2023, and the dossier submitters published an updated proposal in 2025. ECHA’s two scientific committees then carried out their assessments. The Committee for Risk Assessment (RAC) adopted its final opinion on 2 March 2026, concluding that PFAS pose an EU-wide risk justifying restriction. The Committee for Socio-Economic Analysis (SEAC) agreed in its draft opinion on 10 March and published it on 26 March, which opened a 60-day consultation that closed on 25 Mits draft opinion on 10 March and published it on 26 March, openingay. Engagement was heavy, from companies and trade associations to NGOs and researchers across the affected sectors.
The SEAC is now working towards its final opinion, expected by the end of 2026. Once adopted, ECHA will transmit both opinions, together with the original proposal and the comments received, to the European Commission. Only then will the Commission decide whether, and in what form, to propose an amendment to Annex XVII of REACH. Any amendment would be discussed and voted on by Member States in the REACH Committee before scrutiny by the European Parliament and the Council.
A transition whose evidence base is still incomplete
The ECHA Committees’ work underscores the scale and complexity of the transition now envisaged. Three years of stakeholder engagement have not removed the uncertainty. Whether alternatives exist and, on what timeline, substitution is feasible remain unclear for a wide range of uses, as do the socio-economic impacts.
The SEAC’s own conclusions are instructive. It considers a group-based restriction the most appropriate EU-wide measure. It does not endorse a full and immediate ban, which it regards as unlikely to be proportionate given current technical and economic constraints, and instead supports a ban with use-specific derogations. Even that option, on SEAC’s own admission, cannot be confirmed as proportionate overall, because data gaps persist on alternatives, transition timelines and economic impacts across many sectors of use.
This carries particular weight in highly regulated sectors such as healthcare. Substitution there runs through development and validation work followed by regulatory approval, a sequence that cannot be compressed to fit a transition period designed around consumer goods. SEAC recognises that in many cases the available evidence does not yet allow assumptions on alternatives or transition periods to be substantiated.
The draft opinion also gives signals on active pharmaceutical ingredients (APIs). The dossier submitters had proposed time-unlimited derogations for PFAS used as active substances in human and veterinary medicines, as well as in biocidal and plant protection products. The SEAC does not support that approach. It considers a time-unlimited carve-out unjustified and inconsistent with the logic of the rest of the proposal, and recommends time-limited derogations instead. On adjacent uses, among them excipients in ophthalmological and dermatological treatments, medicinal product packaging and broader medical applications, the SEAC concludes that it cannot determine whether the proposed derogations are justified, and recommends short time-limited derogations pending further assessment.
For its part, the RAC notes that existing sectoral legislation on medicinal, biocidal and plant protection products does not fully address PFAS emissions to the environment. Derogations for these uses should therefore be paired with emission-minimisation measures embedded in the relevant sectoral regimes.
The message is plain enough. Essentiality cannot be assumed at sector level. It has to be demonstrated use by use, on the evidence, and it will not be granted indefinitely.
8 additional sectors & the question of proportionality
The aforementioned committees assessed PFAS manufacturing and the 14 sectors set out in the 2023 proposal. When the dossier submitters updated their proposal in 2025, however, they added assessments for eight extra sectors: printing, sealing, machinery, other medical applications, military applications, explosives, technical textiles and broader industrial uses. ECHA concluded that evaluating these eight in the same depth would have pushed the opinion-making process well beyond 2026, and neither committee carried out a sector-specific evaluation of them.
For these eight sectors, the SEAC therefore cannot conclude whether the derogations proposed by the dossier submitters are justified, or whether further derogations would be needed for a restriction to be proportionate. It recommends that the uses concerned be evaluated as soon as possible and that a time-limited derogation apply to all uses within those sectors in the interim, until the evaluation is complete and a proportionality decision can be taken.
Restrictions of this scale stand or fall on the completeness of their analytical basis. Without it, neither credibility nor proportionality can be defended, and the measure becomes legally vulnerable. For the sectors concerned, the outcome is fluid: interim derogations may be maintained, narrowed, broadened or phased out, depending on what evidence reaches the assessment and on when that assessment is finally carried out.
Clear direction, but ambition alone will not be enough
The EU intends to reduce PFAS emissions and accelerate substitution, and the consensus behind a broad group restriction, with derogations confined to genuinely justified uses, is firm. Both committees support EU-wide action. Regulatory clarity and sound sector-specific evidence, delivered against realistic implementation pathways, will decide whether the measure avoids unnecessary disruption in areas critical to healthcare, industrial resilience and Europe’s strategic autonomy.
As the file moves towards the Commission’s decision, the priority is to close the remaining evidence gaps so that the final measure protects the environment and works in practice.
The formal consultation phase has closed. Political and institutional judgements take shape in the period between now and the Commission’s proposal, and that calls for a different kind of engagement from a consultation response.
FIPRA actively monitors and engages on this file, supporting clients to:
- map their PFAS uses against the Committee’s conclusions and identify where their position is exposed, including in the eight unassessed sectors;
- build the use-specific socio-economic evidence needed to substantiate justified uses and realistic transition timelines;
- engage with the Commission, Member States and the European Parliament as the file moves from opinion to legislative proposal and through the REACH Committee and scrutiny stages.
FIPRA’s presence in Brussels as well as the EU 27 via our Global Network enables us to leverage real-time, on-the-ground market intelligence and political insights to help clients understand what’s in it for them. Get in touch to know how we can support your work.
This analysis was conducted by Daniel Laaber and Davide Zampoli, with support from Jan Ahlskog and Darius Movaghar.
